| |  |
| | |
| | DermaGen AB |
| Profile |
The company focuses on developing therapeutic products based on novel endogenous antimicrobial peptides.
DermaGen’s approach is to develop proprietary novel antimicrobial peptides (AMPs) based on human endogenous proteins from major and evolutionary significant human defence systems of the innate immunity network.
The projects are taken to PoC studies and thereafter offered to global pharmaceutical industries.
|
| CEO | Jan Alenfall |
| Region | Medicon Valley |
| Webpage | http://www.dermagen.se |
| E-mail address | info@dermagen.se |
| Contact | Scheelevägen 22
223 63 Lund
Tel + 46 46 192 197
Fax + 46 46 123 536
|